Table 2.
Percent of trials with reported corrective actions to address slow accrual, by phase of trial*
| Categories and Actions to Address Slow Accrual | Phase 1 (n=69) | Phase 2 (n=66) |
|---|---|---|
| Amend the Trial | 55% | 44% |
| Broaden eligibility criteria | 33% | 27% |
| Amend the treatment design (decrease toxicity, statistical design, revise schema) | 20% | 14% |
| Amend the trial-other | 1% | 3% |
| Add Institutions | 43% | 85% |
| Open group-wide/group endorsement | 1% | 5% |
| Add international collaborators | 0% | 3% |
| Place on CTSU | 0% | 5% |
| Activation/IRB approval at planned participating sites | 6% | 27% |
| Add new institutions beyond those originally planned | 36% | 45% |
| Promotion of Trial | 36% | 42% |
| External (reach out to other communities for additional referral base) | 14% | 12% |
| Internal (within own group/CTSU/Cooperative Group system) | 19% | 27% |
| Increase awareness through advocacy groups and professional societies | 3% | 2% |
| Promotion-other | 0% | 2% |
| Administrative/Institutional Processes | 29% | 26% |
| Broaden patient screening activities (by study team) to identify eligible patients | 6% | 6% |
| Increase study team review processes, meetings, conference calls around trial | 7% | 5% |
| Increase/change staffing | 4% | 5% |
| Change administrative processes (streamlining, increase efficiencies) | 4% | 3% |
| Close competing trials internally | 4% | 3% |
| Administrative-other | 3% | 5% |
| Funding | 6% | 11% |
| Increase per case funding | 0% | 5% |
| Obtain additional funding | 6% | 6% |
| Proposed element not considered an action | 32% | 23% |
| No action provided | 13% | 2% |
*
Sorted in descending order for Phase 1 trial corrective actions